Haptoglobin inhibits phospholipid transfer protein activity in hyperlipidemic human plasma by Henderson, Ryan J et al.
BioMed  Central
Page 1 of 8
(page number not for citation purposes)
Lipids in Health and Disease
Open Access Research
Haptoglobin inhibits phospholipid transfer protein activity in 
hyperlipidemic human plasma
Ryan J Henderson, Kishor M Wasan and Carlos G Leon*
Address: Division of Pharmaceutics and Biopharmaceutics, Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, 
British Columbia, V6T 1Z3, Canada
Email: Ryan J Henderson - hendersonrx@gmail.com; Kishor M Wasan - kwasan@interchange.ubc.ca; 
Carlos G Leon* - cleon@interchange.ubc.ca
* Corresponding author    
Abstract
Background: Haptoglobin is a plasma protein that scavenges haemoglobin during haemolysis.
Phospholipid Transfer Protein (PLTP) transfers lipids from Low Density Lipoproteins (LDL) to High
Density Lipoproteins (HDL). PLTP is involved in the pathogenesis of atherosclerosis which causes
coronary artery disease, the leading cause of death in North America. It has been shown that
Apolipoprotein-A1 (Apo-A1) binds and regulates PLTP activity. Haptoglobin can also bind to Apo-
A1, affecting the ability of Apo-A1 to induce enzymatic activities. Thus we hypothesize that
haptoglobin inhibits PLTP activity. This work tested the effect of Haptoglobin and Apo-A1 addition
on PLTP activity in human plasma samples. The results will contribute to our understanding of the
role of haptoglobin on modulating reverse cholesterol transport.
Results: We analyzed the PLTP activity and Apo-A1 and Haptoglobin content in six hyperlipidemic
and six normolipidemic plasmas. We found that Apo-A1 levels are proportional to PLTP activity in
hyperlipidemic (R2 = 0.66, p < 0.05) but not in normolipidemic human plasma. Haptoglobin levels
and PLTP activity are inversely proportional in hyperlipidemic plasmas (R2 = 0.57, p > 0.05). When
the PLTP activity was graphed versus the Hp/Apo-A1 ratio in hyperlipidemic plasma there was a
significant correlation (R2 = 0.69, p < 0.05) suggesting that PLTP activity is affected by the combined
effect of Apo-A1 and haptoglobin. When haptoglobin was added to individual hyperlipidemic
plasma samples there was a dose dependent decrease in PLTP activity. In these samples we also
found a negative correlation (-0.59, p < 0.05) between PLTP activity and Hp/Apo-A1. When we
added an amount of haptoglobin equivalent to 100% of the basal levels, we found a 64 ± 23%
decrease (p < 0.05) in PLTP activity compared to basal PLTP activity. We tested the hypothesis that
additional Apo-A1 would induce PLTP activity. Interestingly we found a dose dependent decrease
in PLTP activity upon Apo-A1 addition. When both Apo-A1 and Hpt were added to the plasma
samples there was no further reduction in PLTP activity suggesting that they act through a common
pathway.
Conclusion: These findings suggest an inhibitory effect of Haptoglobin over PLTP activity in
hyperlipidemic plasma that may contribute to the regulation of reverse cholesterol transport.
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Background
Haptoglobin is an acute phase protein that scavenges hae-
moglobin released into the circulation [1]. Haptoglobin,
the plasma protein with highest binding affinity to hae-
moglobin, is mainly expressed in the liver [2]. It plays an
anti-oxidant role by binding free haemoglobin and form-
ing a complex that is taken up by hepatocytes and macro-
phages [3]. The human haptoglobin gene encompasses
three alleles: Hp1F, Hp1S and Hp2 [4]. The Hp2 allele is
the fusion product of the Hp1F and Hp1S alleles. Hap-
toglobin presents as a dimer of two of these alleles which
binds to one haemoglobin dimer [2]. Haptoglobin
expression is induced several fold in the event of inflam-
mation triggered by infection, injury or cancer develop-
ment [1,5]. Haptoglobin has been shown to play an
antioxidant/anti-inflammatory role, to contribute to neu-
trophil activation [6], to maintain reverse cholesterol
transport [7] and to modulate the inhibition of cyclooxy-
genase and lipooxygenase [8], amongst other functions.
In particular, haptoglobin has been shown to inhibit Lec-
ithin-Cholesterol Acyltransferase (LCAT) in human ovar-
ian follicular fluid [9]. LCAT is involved in the removal of
cholesterol excess from peripheral tissues [10]. LCAT
transfers an acyl chain from high density lipoprotein
(HDL) lecithin to cellular cholesterol. This activity is stim-
ulated by the presence of Apo-A1, the main protein con-
stituent of HDL. Balestrieri et al [9] demonstrated that
LCAT activity is negatively correlated with the Hp/Apo-A1
ratio in human follicular fluid. The mechanism of action
of haptoglobin inhibition of LCAT activity has been
described [11]. The binding site of Haptoglobin on Apo-
A1 has been mapped and it was demonstrated that the
interaction of haptoglobin to Apo-A1 is independent to
the binding of haptoglobin and haemoglobin. A peptide
designed based on the sequence in Apo-A1 that putatively
interacts with Haptoglobin was shown to restore LCAT
activity inhibited by Hp demonstrating that the Apo-A1-
Hp interaction is responsible for the inhibition of LCAT
activity. Based on this evidence it has been speculated that
haptoglobin may play a role in the inhibition of reverse
cholesterol transport.
In the present study we investigated the effect of hap-
toglobin on the activity of another enzyme involved in
reverse cholesterol transport, phospholipid transfer pro-
tein (PLTP). PLTP is a plasma protein that transfers phos-
pholipids from triglyceride-rich lipoproteins such as very
low-density lipoproteins (VLDL) and low-density lipo-
proteins (LDL) to high density lipoproteins (HDL)
[12,13]. PLTP occurs in plasma as two main forms: a high
activity PLTP (HA-PLTP) and a low activity PLTP (LA-
PLTP). HA-PLTP is associated with the majority of plasma
PLTP activity. PLTP activity has been shown to be affected
by its association to Apo-A1 [14,15]. There is increasing
evidence supporting the role of PLTP on atherosclerosis
development [16]. Moerland et al., [17] showed in a
transgenic mouse model of PLTP expression that an
acutely increased PLTP expression resulted in a highly
atherogenic lipoprotein profile. Shelly et al., [18] found
that the phospholipid transfer protein deficiency amelio-
rated diet-induced hypercholesterolemia and inflamma-
tion in mice. There is evidence that even a 10% reduction
on PLTP activity can lead to a significant reduction of
atherosclerosis progression [19], highlighting the role of
PLTP on the development of cardiovascular disease.
In the present study we hypothesize that haptoglobin
inhibits PLTP activity. This is based on the fact that PLTP
activity is dependent on its binding to Apo-A1 [15] and
that haptoglobin has been shown to bind Apo-A1 [11]
and to inhibit LCAT activity [9]. This work will further
contribute to our understanding of the role of hap-
toglobin on modulating reverse cholesterol transport as
well as the development of atherosclerosis.
Results
Haptoglobin and Apolipoprotein A1 levels in 
normolipidemic and hyperlipidemic human plasma
Haptoglobin and Apo-A1 levels were determined for each
one of the plasma samples (Table 1). When the Hp levels
were compared between the two groups (hyperlipidemic
vs. normolipidemic) no difference was found. Likewise,
when the levels of Apo-A1 were compared amongst the
two groups they were not different.
Inverse association between PLTP activity and 
haptoglobin levels in hyperlipidemic plasma
We determined the PLTP activity as described elsewhere
[20]. When we graphed the PLTP activity vs. the hap-
toglobin levels we found a trend of a correlation (Figure
Table 1: Apolipoprotein A1 (μg/mL) and Haptoglobin (μg/mL) 
levels in hyperlipidemic (H1-H6) and normolipidemic (N1-N6) 
plasmas used in this study (mean ± SD). 
Plasma # Apo-A1 (μg/mL) Haptoglobin (μg/mL)
H1 3.9 ± 0.1 5897.7 ± 527
H2 23.2 ± 1.9 5240.4 ± 110
H3 275.7 ± 13 1245.7 ± 28
H4 265 ± 26 4579.9 ± 259
H5 185.8 ± 9 318.6 ± 14
H6 167.3 ± 7 3891.1 ± 231
N1 161.2 ± 4.9 500.5 ± 41
N2 186.2 ± 16 6104.2 ± 134
N3 201 ± 2.1 1480 ± 99
N4 54.8 ± 3 4126.5 ± 124
N5 269.9 ± 34 1322.7 ± 48
N6 337.7 ± 28 3125.5 ± 48
Apo-A1 and haptoglobin were measured as described in Materials and 
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1a R2 = 0.57, Correlation coefficient -0.75) albeit not sig-
nificant (p = 0.08). In the case of the normolipidemic
plasma there was no indication of a correlation (Figure
1b).
Direct association between PLTP activity and Apo-A1 
levels in hyperlipidemic plasma. Correlation between the 
PLTP activity and the Hp/Apo-A1 ratio in hyperlipidemic 
plasma
When we compared the PLTP activity vs. the Apo-A1 levels
we found a positive correlation between these two varia-
bles (Figure 2a, R2 = 0.66, Correlation coefficient 0.81, p <
0.05) in hyperlipidemic plasma but not in normolipi-
demic plasma (Figure 2b).
Based on the model of LCAT inhibition by haptoglobin,
we determined the relationship between PLTP activity and
Ht/Apo-A1 ratio (Figure 2c) in hyperlipidemic plasma. A
negative linear correlation was found (R2 = 0.69, p < 0.05)
suggesting an inhibitory role of haptoglobin on PLTP
activity in this group of plasmas. When a semi logarithmic
non linear regression was used, we obtained a higher cor-
relation (R2 = 0.998) than with the linear model.
Inhibition of PLTP activity by the addition of increasing 
concentrations of haptoglobin
To further examine the inhibition of PLTP activity,
increasing amounts of haptoglobin were added to our set
of plasma samples (Figure 3a). Five out of six hyperlipi-
demic plasma showed a decreased PLTP activity with an
increasing dose of added haptoglobin, irrespective of the
basal PLTP activity. On the other hand, the three normol-
ipidemic plasma samples analyzed didn't show any clear
trend which is in agreement with our previous results
which do not indicate a role of haptoglobin inhibition in
this group. We further analyzed the data expressing it as
percentage inhibition of PLTP activity and found a signif-
icant decrease on PLTP activity in the hyperlipidemic
plasma after 5 min of haptoglobin addition (Figure 3b).
This effect was reduced after 60 min of haptoglobin addi-
tion (Figure 3c). When we analyzed the PLTP activity vs.
the Hp/Apo-A1 ratio, we also found a negative correlation
(Figure 3d, -0.697, p = 0.0217 and n = 11). Based on the
initial amount of haptoglobin in each plasma sample, we
added this specific amount of haptoglobin to each sam-
ple. The effect was a 64% reduction in PLTP activity com-
pared to untreated controls (Figure 4, p < 0.05). This fact
further supported an inhibitory role of haptoglobin over
PLTP activity in vitro.
Inhibition of PLTP activity by the addition of increasing 
concentrations of haptoglobin
We further explored the possible role of Apo-A1 on the
haptoglobin inhibition of PLTP activity. Interestingly, we
found that Apo-A1 inhibited the PLTP activity in the six
hyperlipidemic plasmas (Figure 5a). We also confirmed
the Hp inhibitory effect on PLTP. When both Apo-A1 and
Hp were added, no additive effect was observed (Figure
5b) suggesting that their inhibitory effect occurs through
a common mechanism.
Discussion
Haptoglobin genotype has been shown to regulate reverse
cholesterol transport in diabetes in vitro and in vivo [21]. It
has been proposed that an enhanced oxidative modifica-
tion of serum lipoproteins (LDL and HDL) in individuals
with the Hp2 genotype is an important determinant of
accelerated atherosclerosis in these individuals [22]. Inter-
estingly, PLTP has been shown to efflux cholesterol Apo-
A1 in murine macrophages [23].
Another mechanism by which haptoglobin may regulate
reverse cholesterol transport is by inhibiting LCAT [9].
Since this inhibition is mediated through the Hp-Apo-A1
interaction [11], we propose that other enzymatic activi-
ties regulated by Apo-A1 may be affected by haptoglobin
levels. In particular, we are interested in PLTP which is an
important enzyme involved in reverse cholesterol trans-
port [13] and its activity has been shown to be dependent
on its association with Apo-A1 [15]. The positive correla-
tion between PLTP activity and Apo-A1 levels in hyperlip-
idemic plasma persisted. However, we didn't observe this
correlation in normolipidemic patients. A positive corre-
lation was found between PLTP activity and Apo-A1 in
plasma from patients with type 1 diabetes [24] which is
consistent with our observations. These authors had pre-
viously demonstrated that patients with type 1 diabetes
have a significantly elevated PLTP activity and that this
activity is correlated with HDL levels [25]. One of the dif-
ferences between the two plasma groups that we used was
the HDL content. We found a negative correlation (p =
0.018) between PLTP activity and HDL levels. This corre-
lation was specific to HDL as it was not found with total
cholesterol and triglycerides. Colhoun et al., [24] showed
differences between the correlation of PLTP activity and
HDL particle size. PLTP activity negatively correlated with
small HDL while it positively correlated with large HDL.
Soro et al., [26] also showed a negative correlation
between HDL2 and PLTP activity. Since there is an associ-
ation between reduced HDL particle size and hyperlipi-
demia [27], it is possible that in our hyperlipidemic
patient group there is a higher small HDL/large HDL ratio
than in normolipidemic controls and this contributes to a
negative correlation between PLTP activity and HDL.
One of the limitations of our study is the sample size.
However the correlations that we observed in the basal
state were maintained even when exogenous Hp and Apo-
A1 were added to the system. Nevertheless, Salvatore et
al., [28] found a correlation between the cholesteryl ester/Lipids in Health and Disease 2009, 8:27 http://www.lipidworld.com/content/8/1/27
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cholesterol ratio (a measure of LCAT activity) and Hp/
[Apo E +Apo-A1] ratio in a small number of multiple scle-
rosis patients (n = 9).
When we compared haptoglobin levels with PLTP activity,
the correlation was insignificant (p = 0.08). However,
when we changed our analysis to compare PLTP activity
with Hp/Apo-A1 ratio, we did find a negative correlation
suggesting a) that haptoglobin may inhibit PLTP activity
and b) that Apo-A1 levels may affect this inhibitory inter-
action.
We further confirmed the Hp inhibitory effect by adding
exogenous haptoglobin to the plasma samples. In hyperl-
ipidemic plasma, PLTP activity was inhibited by hap-
toglobin addition in a dose-dependent way. This effect
was not seen in normolipidemic plasma. This effect could
also be related to the differences in low activity and high
activity PLTP in hyperlipidemic and normolipidemic
plasma and the differential association of Apo-A1 to these
two forms of PLTP [14]. The fact that PLTP activity is neg-
atively correlated with the Hp/Apo-A1 ratio in hyperlipi-
demic plasma has not been previously reported.
Conclusion
PLTP activity was inhibited by Haptoglobin and Apo-A1
addition. Haptoglobin, HDL and PLTP activity correlation
data suggests the potential to use haptoglobin as a
biomarker for the development of atherosclerosis as well
as a tool to understand the role of PLTP activity and hap-
toglobin levels in reverse cholesterol and atherosclerosis.
Materials and methods
Chemicals
PLTP Activity Assay Kit's were obtained from Roar Bio-
medical (New York, NY, USA). Purified Hpt (at least 95%
pure by SDS-PAGE) was purchased from Calbiochem
(San Diego, CA). Apolipoprotein A1 was purchased from
Sigma-Aldrich (St Louis, MI).
Plasma Samples
Twelve different human plasma samples (purchased from
Bioreclamation [East Meadow, NY, USA]) were obtained
from donors representing both normolipidemic plasma
(N = 6) and hyperlipidemic plasma (N = 6) based on the
standards set by the Ministry of Health and Welfare of
Japan (cholesterol <220 mg/dl and triglycerides <150 mg/
dl) [29]. The cholesterol and triglyceride content of each
one of these twelve samples has been reported previously
[20].
Haptoglobin determination
Haptoglobin levels were determined using a two site
Human Haptoglobin ELISA kit from ICL (Newberg, OR)
as per the manufacturer instructions. Briefly, the control,
standard and patient samples were added to the wells
which had previously adsorbed the anti-Hp antibodies.
The unbound proteins were removed by washing, and
then anti-Hp antibodies conjugated to horseradish perox-
idase were added. These enzyme-labeled antibodies form
complexes with the previously bound plasma Hp. Follow-
ing washings, a chromogenic substrate was added and
absorbance was read at 450 nm. The concentration of Hp
was determined using a standard curve of purified Hp.
Apo-A1 determination
The human Apo-A1 EIA kit was purchased from Cayman
Chemical Company (Ann Arbor, MI). Briefly each well of
the plate provided with the kit was coated with an Apo-A1
specific antibody. When the samples and controls were
a. Association between PLTP activity and haptoglobin levels  in hyperlipidemic plasma (R2 = 0.5733, n = 6) Figure 1
a. Association between PLTP activity and hap-
toglobin levels in hyperlipidemic plasma (R2 = 0.5733, 
n = 6). PLTP activity after 60 min was determined as 
described in Materials and Methods. Haptoglobin levels were 
determined using a two site Human Haptoglobin ELISA kit. 
Each plasma sample was analyzed in two independent experi-
ments, with at least two replicates per experiment. b. Asso-
ciation between PLTP activity and haptoglobin levels in 
normolipidemic plasma (R2 = 0.0007, n = 6). PLTP activity 
after 60 min was determined as described in Materials and 
Methods. Haptoglobin levels were determined using a two 
site Human Haptoglobin ELISA kit. Each plasma sample was 
analyzed in two independent experiments, with at least two 
replicates per experiment.
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a. Association between Apolipoprotein A1 levels and PLTP activity (60 min) in hyperlipidemic plasma Figure 2
a. Association between Apolipoprotein A1 levels and PLTP activity (60 min) in hyperlipidemic plasma. Apolipo-
protein levels were determined using an EIA kit as outlined in Materials and Methods. Each plasma sample was analyzed in two 
independent experiments, with at least two replicates per experiment. The graph depicts the mean ± standard deviation (R2 = 
0.6635, n = 6, p < 0.05). b. Association between Apolipoprotein A1 levels and PLTP activity (60 min) in normolipidemic plasma 
(R2 = 0.2732, n = 6, p > 0.05). c. Association between PLTP activity (60 min) and Hp/Apo-A1 ratio in hyperlipidemic plasma (R2 
= 0.69, n = 6, p < 0.05).
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a. Effect of haptoglobin addition (2, 10 and 20 μg per sample) on PLTP activity (5 min) of individual hyperlipidemic (H, n = 6)  and normolipidemic (N, n = 2) plasma samples Figure 3
a. Effect of haptoglobin addition (2, 10 and 20 μg per sample) on PLTP activity (5 min) of individual hyperlipi-
demic (H, n = 6) and normolipidemic (N, n = 2) plasma samples. From left to right: control, addition of 2 μg, 10 μg 
and 20 μg of Hp, respectively. One of two representative experiments with duplicate measurements per treatment. b. Effect of 
haptoglobin addition (2, 10 and 20 μg per sample) on PLTP activity (5 min) in hyperlipidemic plasma as a percentage of basal 
PLTP activity. Each plasma sample was analyzed in two independent experiments, with at least two replicates per experiment. 
The graph depicts the mean ± standard deviation of each group of six hyperlipidemic plasma (n = 6, p < 0.05). c. Ibidem, except 
that PLTP activity was analyzed after 60 min. d. Correlation between PLTP activity and Hp/Apo-A1 ratio in hyperlipidemic 
plasma samples with added haptoglobin (n = 11, Correlation coefficient -0.679, p < 0.05).Lipids in Health and Disease 2009, 8:27 http://www.lipidworld.com/content/8/1/27
Page 7 of 8
(page number not for citation purposes)
added to the wells any Apo-A1 would bind to these anti-
bodies. After washings a new anti Apo-A1 antibody was
added to detect the captured Apo-A1. Washings were fol-
lowed by the addition of horseradish peroxidase conju-
gate that will recognize the complex. Upon washings and
addition of a chromogenic substrate, the reaction was
stopped with acid and absorbance was read at 450 nm.
The intensity of the color is proportional to the concentra-
tion of Apo-A1 which was determined using a standard
curve.
PLTP Assay
Each plasma sample was tested for PLTP activity using an
activity assay that measures in vitro phospholipid transfer
activity (Roar Biomedical, New York, NY). The PLTP assay
was carried as per manufacturer instructions as described
previously [20]. Initially, the PLTP activity test was studied
for different concentrations of plasma protein and it was
decided to be 25 μg as the PLTP activity was linear in this
range. PLTP activity was determined for plasma samples
(25 μg). Controls were added in the form of a picomol
standard to quantify PLTP activity and a blank control.
Plates also measured plasma activity as a single entity in
the PLTP kit. Measurements were taken for 6 different
plasma samples in the hyperlipidemic range and 6 differ-
ent plasma samples in the normolipidemic range. These
samples were done in duplicate on each 96-well test plate
and each test plate was repeated at least twice for each
plasma sample.
Statistical Analysis
The groups tested in this study were compared against
each other by applying a repeated measure analysis of var-
iance (ANOVA) test and blocking results in set plasmas to
account for base PLTP activity variance. Statistical differ-
ences in the data was considered significant if the p value
found was < 0.05. Data added for each plasma measure
consisted of an N = 6 of which each experiment had at
least a replicate value of 2.
The strength and direction of a linear relationship
between two random variables was measured by the Pear-
son's coefficient of correlation as determined using Sigm-
aStat™.
Abbreviations
Hp: Haptoglobin; PLTP: Phospholipid transfer protein;
Apo-A1: Apolipoprotein A1; HDL: High density lipopro-
tein; LDL: Low density Lipoprotein.
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a. Effect of Apo-A1 addition to the rate of PLTP activity  within the first 60 minutes of reaction in hyperlipidemic  plasma Figure 5
a. Effect of Apo-A1 addition to the rate of PLTP 
activity within the first 60 minutes of reaction in 
hyperlipidemic plasma. Two and four micrograms of 
Apo-A1 were added to the plasma samples and PLTP activity 
was measured within the first two and 60 minutes to calcu-
late the rate of activity (nmoles product/min). One of two 
representative experiments. b. Effect of Apo-A1 and Hap-
toglobin addition to the rate of PLTP activity within the first 
60 minutes of reaction in hyperlipidemic plasma. Two micro-
grams of Apo-A1 and/or the equivalent of 100% of basal hap-
toglobin were added to the plasma (Pl: plasma alone, Pl+Apo-
A1: plasma plus Apo-A1, Pl+Hp: plasma plus haptoglobin and 
Pl+Apo-A1+Hp: plasma plus Apo-A1 plus Haptoglobin) and 
PLTP activity was measured within the first two and 60 min-
utes to calculate the rate of activity (nmoles product/min). 
One of three representative experiments.
Effect of Haptoglobin addition on PLTP activity (5 min) in  hyperlipidemic plasma Figure 4
Effect of Haptoglobin addition on PLTP activity (5 
min) in hyperlipidemic plasma. The equivalent of 100% 
of basal haptoglobin levels was added to each plasma sample 
and PLTP activity was measured as described previously (n = 
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